GlobeNewsWire · TRAW · November 12, 2026

Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID®

Get the app for more

Explore stock news, insights and company research.